Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
FlowCardia is a medical device company marketing catheters that reopen obstructed arteries in the legs, which can avoid amputation. Its lead product, the CROSSER™, uses high-frequency vibration to penetrate hard arterial blockages.
After Gilde led a large institutional financing round of growth capital, the company built a marketing and sales organization, expanded its product portfolio and developed into a high-growth, revenue-generating business. FlowCardia was acquired by C. R. Bard, Inc. (NYSE: BCR) in 2010. It was located in Sunnyvale, California.
More Flowcardia news
FlowCardia, Inc. Initiates CENTRAL Study Enrollment
FlowCardia, Inc. expands treatment options for patients with chronic total occlusion
FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance
FlowCardia, Inc. Appoints Deborah DeFilippo CFO
Venture&Growth
ADCendo
Danish Therapeutics company focused on antibody-drug conjugates (ADCs) for the treatment of cancers.
Venture&Growth
AM-Pharma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI).
Venture&Growth
Nyxoah
Belgian Healthtech company focused on the treatment of sleep apnea.